FOR IMMEDIATE RELEASE

BioView Ltd Signs Mutual Reserch Agreement with The University of Texas M.D. Anderson Cancer Center

Rehovot, Israel – May, 2006  –BioView Ltd., developer and distributor of scanning systems for cancer detection, signed an agreement with The University of Texas M. D. Anderson Cancer Center, Houston, Texas for the development of a diagnostic test for early detection of lung cancer in high-risk populations. BioView will develop applications that will enable rapid and accurate identification of malignant cells using DNA probes developed by researchers at M. D. Anderson.

The proposed diagnostic test will be based on BioView’s Duet (a scanning platform enabling automatic scanning and identification of cell samples with a proprietary software aimed for specific application) in combination with DNA probe research and development performed by M. D. Anderson researchers. The mutual work is planned to continue into 2007.

Opher Shapira, BioView CEO says that the company is focusing its development efforts in the cancer area – both in automation of existing tests and in the development of new tests. In this framework the company is working to develop the lung cancer test.  “We are very pleased to have signed this agreement with University of Texas M.D Anderson Cancer Center.  This development is a natural continuation to BioView target to continue developing new tests for better cancer treatment.” says Shapira.

BioView completed about a month ago its first IPO in the Tel Aviv Stock Exchange, and raised 24 Millions NIS in stocks and options.  The company develops, sells and markets its automatic systems for the identification of irregular cells and the development of cancer tests.  The scanning systems of the company are used today to scan blood, bone marrow, urine and amniotic fluid.

The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. This year, more than 74,000 patients with cancer will receive care at M. D. Anderson, and about 27,000 of them will be new patients. More than 11,000 cancer patients participated in therapeutic clinical research exploring novel treatments in 2005, the largest such program in the United States.

At M. D. Anderson, important scientific knowledge gained in the laboratory is rapidly translated into clinical care. In 2005, the institution spent more than $342 million in research, an increase of approximately 86 percent in the last five years.